Literature DB >> 8443697

Long- and short-term side effects and safety of calcitonin in man: a prospective study.

S J Wimalawansa1.   

Abstract

Forty-three patients were treated for a total duration of 301 patient-years with calcitonin (CT) (range 3-16 years, median duration 6 years 6 months). Eighty-four percent of patients were suffering from complications associated with Paget's disease and the remainder from osteoporosis. In the majority of patients, CT was administered by the subcutaneous route and one patient was psychologically dependent on calcitonin injections. There were no long-term side effects associated with CT therapy. In a separate group of 105 patients consisting of 83 patients on human CT and 22 patients on salmon CT, injections showed short-term side effects in 77% and 64% of these patients, respectively (NS). Side effects associated with nasally administered salmon CT in 25 patients were mild and of low incidence (32%). Long-term administration of calcitonin in humans is safe and devoid of any serious or long-term side effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443697     DOI: 10.1007/bf00308314

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  35 in total

Review 1.  Calcitonin binding sites in bone: relationships to biological response and "escape".

Authors:  A H Tashjian; D R Wright; J L Ivey; A Pont
Journal:  Recent Prog Horm Res       Date:  1978

2.  Nasal calcitonin for treatment of established osteoporosis.

Authors:  K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

3.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

4.  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

Authors:  S H Ralston; S J Gallacher; U Patel; F J Dryburgh; W D Fraser; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

5.  Loss of calcemic effects of calcitonin and parathyroid hormone infused continuously into rats using the Alzet osmotic minipump.

Authors:  J F Obie; C W Cooper
Journal:  J Pharmacol Exp Ther       Date:  1979-06       Impact factor: 4.030

6.  Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia.

Authors:  O L Bijvoet; J van der Sluys Veer; A P Jansen
Journal:  Lancet       Date:  1968-04-27       Impact factor: 79.321

7.  Effects of diphosphonates in hypercalcaemia due to neoplasia.

Authors:  J A Kanis; R C Percival; A J Yates; G H Urwin; N A Hamdy
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

8.  Inhibitory effect of calcitonin on growth hormone and insulin secretion in man.

Authors:  L Cantalamessa; A Catania; E Reschini; M Peracchi
Journal:  Metabolism       Date:  1978-08       Impact factor: 8.694

9.  An evaluation of antibodies and clinical resistance to salmon calcitonin.

Authors:  F R Singer; J P Aldred; R M Neer; S M Krane; J T Potts; K J Bloch
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

Review 10.  Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.

Authors:  F R Singer; R S Fredericks; C Minkin
Journal:  Arthritis Rheum       Date:  1980-10
View more
  11 in total

1.  Calcitonin effects on shoulder adhesive capsulitis.

Authors:  Alireza Rouhani; Mohsen Mardani-Kivi; Mohammadreza Bazavar; Mahmood Barzgar; Ali Tabrizi; Keyvan Hashemi-Motlagh; Khashayar Saheb-Ekhtiari
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-07-08

Review 2.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

3.  Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.

Authors:  J M Cardona; E Pastor
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease.

Authors:  Y Sato; S Manabe; H Kuno; K Oizumi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

Review 5.  [Overview of animal researches about the effects of systemic drugs on implant osseointegration].

Authors:  Ya-Nan Wang; Ting-Ting Jia; Xin Xu; Dong-Jiao Zhang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

Review 6.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 7.  Current and potential future drug treatments for osteoporosis.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

8.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

9.  Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.

Authors:  S J Wimalawansa; R D Gunasekera
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

10.  The Role of KV7.3 in Regulating Osteoblast Maturation and Mineralization.

Authors:  Ji Eun Yang; Min Seok Song; Yiming Shen; Pan Dong Ryu; So Yeong Lee
Journal:  Int J Mol Sci       Date:  2016-03-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.